Genetic disorders in the GH–IGF-I axis in mouse and man

M J E Walenkamp and J M Wit
Department of Pediatrics J6-S, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
(Correspondence should be addressed to M J E Walenkamp; Email: m.walenkamp@lumc.nl)

Abstract
Animal knockout experiments have offered the opportunity to study genes that play a role in growth and development. In the last few years, reports of patients with genetic defects in GH–IGF-I axis have greatly increased our knowledge of genetically determined causes of short stature. We will present the animal data and human reports of genetic disorders in the GH–IGF-I axis in order to describe the role of the GH–IGF-I axis in intrauterine and postnatal growth. In addition, the effects of the GH–IGF-I axis on the development and function of different organ systems such as brain, inner ear, eye, skeleton, glucose homeostasis, gonadal function, and immune system will be discussed. The number of patients with genetic defects in the GH–IGF-I axis is small, and a systematic diagnostic approach and selective genetic analysis in a patient with short stature are essential to identify more patients. Finally, the implications of a genetic defect in the GH–IGF-I axis for the patient and the therapeutic options will be discussed.

European Journal of Endocrinology 157 S15–S26

Introduction
Reports of patients with genetic defects in growth hormone–insulin-like growth factor-I (GH–IGF-I) axis, in addition to animal knockout experiments, have considerably increased our knowledge of the role of the GH–IGF-I axis in growth and development throughout life. By means of these reports we will describe the factors playing a role in intrauterine as well as postnatal growth and the effect of the GH–IGF-I axis on the development and function of different organs. Finally, the tools for the diagnostic approach for the physician and the clinical implications for the patients will be discussed.

Intrauterine growth
The first evidence that intrauterine growth is determined by GH-independent IGF-I secretion comes from animal experiments. Mice with severe GH deficiency due to spontaneous mutations in the genes encoding GH-releasing hormone receptor (GHRHR) (little mouse), Pit 1 (Snell dwarf), and Prop-1 (Ames dwarf) have a normal birth weight (1). The GH-insensitive Laron mouse is born with a normal body size and weight (2). In contrast, IGF-I and IGF-I receptor (IGF1R) knockout mice have birth weights of 60 and 45% of normal respectively. From these observations, it was concluded that IGF-I is a growth determinant factor for intrauterine growth, independently of GH (3–5). The effects of IGF-I are mediated by the IGF1R, which is in line with the observation that the IGF1R−/− mice and the IGF1R−/− IGF-I−/− mice are equally growth retarded at birth (45% of normal) (3). IGF1R−/− knockout mice die within minutes after birth due to respiratory failure (3). IGF1R−/− mice are phenotypically normal (3). Disruptions in the IGF-I signaling pathway as described in mice deficient in Akt1, insulin receptor substrate-1 (IRS-1) or IRS-2 result in reduced intrauterine growth (6–9).

In the human, GH deficiency and insensitivity result in a normal birth size (10–12). In contrast, an IGF-I gene deletion or mutation results in severe intrauterine growth retardation as is demonstrated in the patient described by Woods et al. (birth weight and length: −3.9 and −5.4 SDS respectively), Walenkamp et al. (−3.9 and −4.3 SDS respectively) and Bonapace et al. (−4 and −6.5 SDS respectively) (13–15). The finding that genetically determined low IGF-I levels, due to polymorphisms in the IGF-I promoter region, result in a reduced birth weight and length support the role of IGF-I in fetal growth (16, 17).

There are also indications of an IGF-I dose effect on intrauterine growth. IGF-I heterozygous mice are 10–20% smaller at birth (4), and in the human we found that carriers of an IGF-I missense mutation have a 10% lower birth weight than noncarriers (14).

In contrast to the observations in mice, heterozygous mutations of the IGF1R result in intrauterine growth...
retardation in the human (18–22). The degree of intrauterine growth retardation (IUGR) varies between −1.5 and −3.5 SDS for birth weight and between −0.3 and −5.8 SDS for birth length. The different mutations result in a variable degree of remaining IGF-I signaling, which may explain the wide range of birth size. Another hypothesis is that maternal IGF-I resistance during pregnancy in the mothers with a heterozygous IGF1R mutation contributes to more severe growth retardation. This is supported by the finding that children with an affected mother are more growth retarded at birth than children with an apparently non-affected mother (22).

IGF1R haploinsufficiency is associated with a variable degree of intrauterine growth retardation (−1.8 to −5.6 SDS) as is demonstrated in patients with a terminal 15q deletion, including the IGF1R gene (23–30). The report of a patient with three copies of the IGF1R gene supports the concept that a gene dose effect plays a role in intrauterine growth. This patient is born at 42 weeks gestational age with a birth weight of 5140 g, a birth length of 60 cm, and a head circumference of 38.5 cm (28).

So far, genetic defects in the IGF-I signaling pathway are not described in humans. However, in a recent study by Laviola et al., the IRS-2 and Akt pathways were down-regulated in human placentas from pregnancies complicated by IUGR, indicating an important role for IGF-I signaling in the appropriate development of the fetoplacental unit (31).

Acid-labile subunit (ALS) forms a ternary complex with IGF-I or IGF-II and IGF-binding protein (IGFBP)-3 or IGFBP-5 in the circulation to increase the half-life of the IGFs. ALS deficiency appears to have no effect on fetal growth in ALS knockout mice (32). Data on intrauterine growth of ALS-deficient patients are limited, as the first described patient is adopted and gestational age is not available. At the age of one week, weight was 2500 g and length was 47 cm, which is considered normal (33). In addition, from the second patient no data regarding gestation, birth weight or length are available (34). Since expression of ALS occurs late in fetal life (35), severe effects on intrauterine growth are unlikely.

Although this review focuses on genetic defects in the GH–IGF-I axis, the importance of the role of IGF-II in intrauterine growth cannot be left unmentioned. IGF-II acts as an important modulator of placental cell proliferation and maturation (36). A positive correlation has been demonstrated between cord blood IGF-II and placental weight (37). However, controversy exists with regard to the relation between fetal serum IGF-II levels and fetal growth. Some studies report reduced cord blood IGF-II levels in IUGR babies (38–40), while others report similar levels of IGF-II in IUGR and normal fetuses (41). Human mutations in the gene encoding IGF-II, located on 11p15, have not been identified so far. However, alterations in imprinting status of the IGF-II gene are associated with severe IUGR as part of the Silver–Russell syndrome (a condition characterized by severe IUGR, postnatal growth failure, dysmorphic facial features, and body asymmetry). The IGF-II gene is paternally expressed. A maternal duplication of 11p15 or demethylation of the telomeric imprinting center ICR1 on 11p15, resulting in underexpression of IGF-II, is found in 50% of patients with Silver–Russell syndrome (42–44).

Postnatal growth

The first two weeks of postnatal life growth of the Snell dwarf, the Ames dwarf, the little mouse, and the Laron mouse is indistinguishable from the wild-type litters (1). However, at postnatal day 40, their size is about 50% of normal, which confirms the increasing role of GH in postnatal life. The size of the IGF-I knockout mice decreases progressively from 60% of normal at birth to 30% of normal at 8 weeks. Double knockout mice (GHR+/− and IGF-I−/−) have a postnatal growth pattern of 17% of normal (45). These findings demonstrate that GH-dependent IGF-I action is the main determinant of postnatal growth, but that GH and IGF-I have also independent effects (45). Targeted gene deletion of liver-specific IGF-I and ALS, resulting in a 85–90% reduction of circulating IGF-I, shows a 20% lower body weight than control mice. This implicates that, while endocrine IGF-I is important in postnatal growth, tissue IGF-I also plays a role since the total IGF-I−/− mouse is more growth retarded (46).

The classical heterozygous IGF1R−/+ mice are phenotypically normal, with normal expression of IGF1R mRNA, suggesting that the intact wild-type allele is up-regulated and that a single functional IGF1R allele is sufficient to ensure normal growth (3). However, later experiments inducing reduced availability of the IGF1R (41% less than normal) showed a growth deficit of 13 and 6% in males and females respectively, implying that a partial reduction in IGF-I signaling reduces the growth potential, at least in the male mouse (47).

In the human, severe isolated GH deficiency leads to a final height ranging from −3.9 to −6.1 SDS (48). GH deficiency due to GHRHR mutations results in a mean final height of −7.2 SDS (49). Patients with GH insensitivity due to a GHRHR mutation reach a final height varying from −3.2 to −12 SDS (12, 50, 51) and due to a STAT5b mutation from −5.9 to −7.8 SDS (52–54). Complete IGF-I deficiency due to a deletion of the IGF-I gene results in a final height of −6.9 SDS (13). The final height of the patient with an inactivating mutation of the IGF-I gene is −8.5 SDS (14). The height of a patient with a mutation resulting in extremely low IGF-I levels at the age of 19 months is −6.2 SDS (15). These results show that GH deficiency results in a similar growth pattern as
primary IGF-I deficiency, which emphasizes the predominant role of GH-dependent IGF-I production in postnatal growth. Treating GH-deficient patients with GH results in a better growth response than treating GH-insensitive patients with recombinant human (rh)IGF-I, suggesting that a direct GH effect is necessary for optimal postnatal growth (55).

GH insensitivity caused by a STAT5b mutation results in severe postnatal growth retardation in males and females. In contrast, the homozygous ablation of STAT5b in mice results in loss of the sexual dimorphism in body growth: the postnatal growth curves of female wild-type, female STAT5b−/− and male STAT5b−/− mice show no significant difference (56). STAT5b gene disruption in mice leads to a loss of the sexually dimorphic pituitary pulsatile GH secretion pattern and liver gene expression. It is uncertain how this difference with regard to the interaction between sex steroids and the GH–STAT5b–IGF-I axis in mouse versus human can be explained. One explanation may be that in the mouse the growth-promoting effect of the typical male pattern of GH secretion (high GH peaks, low troughs) is transmitted by STAT5b, while the irregular GH profile of female rats, with lower peaks and higher troughs, is primarily transmitted by another signal transduction route. Knocking out STAT5b in the mouse can then be expected to abolish the sexual dimorphism in growth in the rat. In the human, the GH profile is not different between sexes, and is similar to the pattern of GH secretion seen in male rats. A STAT5b defect would then be expected to have a similar effect in both sexes (56, 57).

Patients with IGF-I insensitivity due to IGF1R mutations show more variety in postnatal growth (−0.9 to −4.8 SDS) than patients with IGF-I deficiency. The phenotype variability in IGF-I insensitivity is most probably caused by differences in remaining IGF-I signaling or by a compensatory mechanism that up-regulates the expression of the normal IGF1R allele. In addition, a gene dose effect seems to play a role in postnatal growth as is demonstrated by the severe postnatal growth failure (−3.5 to −6.3 SDS) of patients with IGF1R haploinsufficiency due to a terminal 15q deletion, including the IGF1R gene (23, 25, 26, 28–30). The finding that trisomy of terminal 15q resulting in duplication of the IGF1R gene is associated with tall stature supports this hypothesis (58).

Two patients with ALS deficiency due to a mutation in the ALS gene have been described (33, 34) and we have recently reported two affected siblings (59). They present with a variable degree of growth retardation: height at 14.6 years of age −2.05 SDS and final height −0.8 SDS in the patient described by Domene et al., −2.1 SDS at 15.5 years of age in the patient described by Hwa et al., final height was −4.2 SDS in one of the siblings and height was −4.3 SDS at the age of 16.5 years in the other sibling. Extremely low IGF-I and IGFBP-3 levels are a common finding in all these patients. A high flux of free IGF-I into the tissues and rapid proteolysis of IGF-I can explain this feature. Another possibility is that paracrine and autocrine IGF-I effects, stimulated by increased GH production, compensate for the deficiency of circulatory IGF-I (34).

**Regulation of GH secretion**

The regulation of GH secretion is complex. Briefly, GHRH stimulates GH synthesis and determines the amplitude of the pulses, while the intermittent withdrawal of somatostatin regulates the timing of the GH pulses. The low-amplitude spontaneous GH release in patients with a GHRHR mutation supports this hypothesis (60). The autoregulation mechanism of GH and IGF-I suppresses GHRH and stimulates somatostatin expression.

Age, gender, sex hormones and adiposity influence the magnitude of GH secretion (61). Ghrelin, a hormone predominantly produced in the stomach, stimulates GH release and appetite. Ghrelin−/− mouse has a normal phenotype, suggesting that ghrelin itself is not required for growth (62). Human mutations have not yet been described. Ghrelin acts via the GH secretagog receptor (GHSR). Recently, two families with a GHSR missense mutation resulting in impairment of the constitutive activity of the receptor were identified. The heights of the homozygous probands were −3.7 and −3.2 SDS, supporting the hypothesis that ghrelin signaling via the GHSR plays a role in the GH–IGF-I axis (63).

In patients with GH insensitivity, low IGF-I levels result in loss of negative feedback and as a consequence increased GH secretion. IGF-I therapy restores GH secretion to normal, implying that the sensitivity of the feedback mechanism is intact in these patients (64). In addition to the increased GH secretion, prolactin levels are slightly elevated in patients with GH due to a GHR mutation (65). This may be the result of increased GHRH secretion as a consequence of the diminished negative feedback of IGF-I and GH, which also stimulates the prolactin secretion from somatolactotroph cells in the pituitary. Indeed, the elevated prolactin levels are suppressed upon IGF-I administration, in line with the inhibitory action of IGF-I on hypothalamic GHRH neurons (65). In patients with a STAT5b mutation, prolactin levels are even more elevated (52, 54, 66). This can be explained by the obligatory role of STAT5b in mediating the negative feedback action of prolactin on tuberoinfundibular dopamine neurons: in the absence of STAT5b, the signal transduction in the hypothalamic dopamine neurons is impaired (67).

Patients with IGF-I insensitivity are characterized by elevated IGF-I levels as a result of increased GH production due to pituitary and hypothalamic IGF1R deficiency. This is supported by the finding that IGF1R−/− mice exhibit signs of somatotropic stimulation in the pituitary (61). However, in patients with poor caloric intake IGF-I can be
in the normal range, which should be considered as relatively high for a malnourished infant or child. Restoring the nutritional status increases the IGF-I level above the normal range (22).

Patients with IGF1R haploinsufficiency have normal or elevated IGF-I levels (23, 25, 26, 30). Stimulated GH secretion was normal in all tested patients (24, 26, 28–30). Apparently, IGF1R haploinsufficiency has no major impact on GH and IGF-I secretion.

**IGFBPs**

IGF-I is secreted into the circulation and associates with soluble high-affinity binding proteins, the IGFBPs. IGFBP-3 and IGFBP-5 form a complex with IGF-I and ALS. This ternary complex slows the clearance of IGF-I. Changes in IGFBP expression have an important role in modulating the growth-promoting actions of the IGFs.

In mice, reports of IGFBP knockout models are limited and demonstrate only few phenotypic manifestations (68). Overexpression of IGFBP-1 in transgenic mice results in a modest and transient impairment of fetal growth. In addition, maternal IGFBP-1 excess is associated with reduced fetal weight indicating placental insufficiency (69). In human, there is a striking inverse correlation between maternal and fetal circulating levels of IGFBP-1 and fetal size (39, 44, 70, 71). It is postulated that IGFBP-1 inhibits the growth-promoting effect of IGF-I by binding fetal IGFs in IUGR. Indeed, IGFBP-1 levels and mRNA expression are markedly elevated in the umbilical cord blood of babies with profound and prolonged hypoxia, which is considered a leading cause of IUGR (72). In a recent study, the key role of IGFBP-1 in mediating the effects of hypoxia on fetal growth was confirmed in zebrafish, suggesting this is a conserved physiological mechanism to restrict IGF-stimulated growth under hypoxic conditions (73).

IGFBP-1 is synthesized in the liver, where its expression is under the control of insulin which suppresses its production (74). It has also been suggested that GH directly regulates IGFBP-1 secretion (75). In a patient with the IGF-I deletion, IGFBP-1 was low. This patient was severely insulin resistant and a combination of high insulin levels, the absence of IGF-I, and increased GH levels probably contributed to the low IGFBP-1 levels. Treatment of this patient with rhIGF-I resulted in beneficial effects on insulin resistance, decreased GH secretion, and higher IGFBP-1 levels (76). A patient with the inactivating mutation of the IGF-I gene was not severely insulin resistant and had also low IGFBP-1 levels, suggesting an important role of a direct suppressive effect of GH on IGFBP-1 (14). A patient with ALS deficiency also had low IGFBP-1 levels, which can also be attributed to stimulated GH levels (33).

IGFBP-2 levels were low in the patient with the IGF-I gene deletion. rhIGF-I treatment increased the IGFBP-2 levels (76). IGFBP-2 in the patient with the IGF-I mutation was −1 SDS (14). The patient with ALS deficiency had low IGFBP-2 levels (33). These data suggest that GH plays a role in regulating IGFBP-2 production.

In the absence of ALS, IGFBP-3 is cleared very quickly, resulting in extremely low serum concentrations (33, 77). The transcription of IGFBP-3 is induced by activation of the GH signal transduction pathway, including STAT5b. Therefore, IGFBP-3 is a valuable biochemical parameter in differentiating a GH receptor or postreceptor defect from an IGF-I or IGF1R defect. In the latter, IGFBP-3 levels are normal (13, 14, 22), while in patients with a GHR defect or a STAT5b mutation, IGFBP-3 is low (51, 52, 54, 77).

**The GH/IGF-I axis in brain development**

IGF-I plays a key role in the development of the central nervous system (CNS), stimulating neurogenesis and synaptogenesis, facilitating oligodendrocyte development, promoting neuron and oligodendrocyte survival, and stimulating myelination (78). In addition, IGF-I appears to be a potent agent for rescuing neurons from apoptosis. Since systemic IGF-I is not readily transported through the blood–brain barrier, local production of IGF-I is considered to be responsible for these effects (79).

Psychomotor development is normal in patients with GH deficiency or insensitivity (80). Patients with primary IGF-I deficiency due to a deletion or mutation of the IGF-I gene are severely mentally retarded and microcephalic with a head circumference of −4.9 SDS (13) and −5.7 SDS (15) at birth and of −5.3 SDS (13) and −8 SDS (14) in adulthood, emphasizing the essential role of GH-independent IGF-I production in prenatal brain development. The head circumference of carriers of the inactivating IGF-I mutation is within the normal range. However, carriers have a lower head circumference than noncarriers (−1 vs 0.5 SDS). Microcephaly is a common feature in patients with IGF-I insensitivity due to a heterozygous IGF1R mutation, however less severe than in complete IGF-I deficiency (−3 to −5.6 SDS) (22). Psychomotor development in these patients varies from retarded with an IQ of 60 to completely normal. Head circumference in patients with IGF1R haploinsufficiency due to a terminal 15q deletion is not well documented. In two patients, head circumference measured −5.3 (25) and −3 SDS (26). In most cases, psychomotor development was delayed, but the possible contribution of other genes in the deleted region makes conclusions on a causal relation difficult.

**Hearing**

Recently, the role of IGF-I in auditory function was evaluated. Auditory brainstem responses were analyzed...
in IGF-I−/− mice, showing an all-frequency involved bilateral sensorineuronal hearing loss. The delayed response to acoustic stimuli along the auditory pathway indicates the contribution of the CNS to the hearing loss in IGF-I deficiency (81). At a cellular level, a significant decrease in number and size of auditory neurons, increased apoptosis of cochlear neurons, a significant reduced volume of the cochlea and cochlear ganglion can result in abnormal differentiation and maturation of the cochlear ganglion cells and abnormal innervation of the sensory cells in the organ of Corti (82).

Audiograms of the three patients with complete IGF-I deficiency due to a homozygous deletion or mutation of the IGF-I gene demonstrate severe bilateral sensorineuronal deafness (13–15). This is confirmed by absent brainstem evoked potentials in one of the patients (14). Seven of the 21 family members of the patient with the inactivating IGF-I mutation, including nine carriers of the inactivating IGF-I mutation, reveal hearing abnormalities. However, no significant association with the carriership could be detected (14). In patients with GH deficiency or insensitivity or heterozygous IGF1R receptor mutations, hearing problems have not been reported.

In conclusion, IGF-I is a key factor in development and postnatal differentiation and maturation of the inner ear.

**Vision**

In a recent study, the ocular dimensions of patients with Laron syndrome were compared with reference values. Patients with Laron syndrome have a significantly shorter axial length of the eye and shallower anterior chambers. Treatment with IGF-I increases the axial length of the eye (83). The patient with an inactivating IGF-I mutation has a shallow anterior chamber, suggesting that IGF-I may play a role in ocular growth (14).

Retinal vascularization is significantly reduced in patients with defects in GHR, IGF-I, and IGF1R, indicating that IGF-I plays an important role in this phenomenon (84). A strong association has been found between reduced IGF-I levels in preterm children and development of retinopathy of prematurity. Deficient IGF-I levels after premature birth result in initial poor retinal vascular development and a large area of avascular retina (85).

**Skeletal features**

Limited elbow extensibility is seen in 85% of patients with Laron syndrome over 5 years of age, with increasing severity with age (50). In addition, six out of eight patients with GH deficiency due to a PROP1 mutation show symmetrical limitation of elbow extensibility, correlated with age (86). We also found this feature in a patient with an inactivating mutation of the IGF-I gene, but it was not described in the other patients with IGF-I defects at 19 months and 15.5 years, suggesting that IGF-I plays a role in elbow extensibility later in life. The mechanism is unknown.

Micrognathia is a striking feature in two patients with IGF-I defects. Diewert et al. found that major growth movements and developmental changes in craniofacial tissues take place between 7 and 12 weeks of gestation (87). Significant alterations in growth during this period may produce significant irreversible effects on postnatal craniofacial morphology. One can hypothesize that prenatal IGF-I deficiency may disturb this process and result in micrognathia.

**Bone mineral density (BMD)**

Studies on skeletal structure in IGF-I−/− mice show a 17% decrease in cortical bone but an increase in trabecular bone (23 and 88% in male and female respectively) (88). This phenomenon is also observed in IGF-I deficient double knockout mice (liver-specific IGF-I and ALS deletion) (89). Yakar et al. postulated that the ternary complex (IGF-I, IGFBP-3, and ALS) influences bone acquisition in a compartment-specific manner (i.e., cortical versus trabecular bone). The finding that IGF-I deficient mice exhibit greater impairment in bone accretion than GH-deficient mice implies a GH-independent effect of IGF-I on bone formation during postnatal growth (90).

Dual-energy X-ray absorptiometry is a method to assess BMD (in g per cm²). However, the method does not correct for antero-posterior depth and is therefore greatly influenced by bone size. Bone mineral apparent density (BMAD) calculates volumetric density to minimize the effect of bone size on BMD values (91). This method greatly contributes to the interpretation of BMD in patients with short stature.

Patients with GH deficiency due to GHRHR mutations or GH insensitivity due to GHR mutations have a normal BMAD (92–94). BMAD in a patient with an IGF-I gene deletion is mildly reduced. Treatment with rhIGF-I resulted in a 7% increase of BMAD, compared with a 17% increase of BMD, suggesting that the increase in BMD is partly attributable to an increase in bone size (95). In contrast, severe osteoporosis is demonstrated in a patient with an inactivating IGF-I mutation (14). Two patients with a heterozygous mutation of the IGF1R gene have a normal BMD (18, 22). In one patient with ALS deficiency, severe osteoporosis is found at the age of 16 years (BMD at lumbar spine: −4.6 SDS), with a partial recovery at 19 years of age (BMD at lumbar spine: −2.1 SDS) (96). In a patient we recently described, a similar pattern was observed with an increasing BMD from −5.2 to −4.1 and −2.5 SDS at the age of 16, 17, and 19 years respectively. This suggests that sex steroids can reduce the osteoporotic effects of ALS deficiency during puberty.
Glucose homeostasis

It has been well documented that GH exerts direct effects on insulin secretion as well as indirect effects through increased lipolysis, resulting in elevated free fatty acid (FFA) levels and impaired insulin sensitivity, the 'lipotoxic effect' (97). Acute administration of GH has an insulin-like effect, mediated by the JAK-2 signaling pathway. Activation of insulin receptor substrates IRS-1 and IRS-2 leads to recruitment of PI3 kinase and, analogous to the postreceptor events for insulin, results in increased glucose uptake (98). GH therapy is often associated with impaired insulin sensitivity. Prevention of lipolysis by coadministration of GH with FFA regulators can partially prevent the deterioration of insulin sensitivity, indicating that insulin resistance is a consequence of enhanced GH-induced lipolysis (99). In addition, the GH plus FFA regulator combination treatment significantly enhances linear body growth in SGA and control rats. The precise mechanism of this observation remains to be elucidated (100). Chronic excess of GH, as in acromegaly, is associated with insulin resistance and impairment of insulin receptor signal transduction. Treatment of acromegalic patients with somatostatin analogs improves insulin resistance (101). Postreceptor crosstalk between the insulin receptor and GH receptor signaling pathways is believed to play a key role in this process (102).

IGF-I, which has 48% amino acid sequence identity with proinsulin, enhances insulin sensitivity. Epidemiological studies have demonstrated that lower baseline IGF-I levels are associated with a higher risk of insulin resistance (103). Genetically determined low IGF-I levels are associated with an increased risk of insulin resistance (104). Treatment with rhIGF-I improves insulin sensitivity in normal individuals (105), in patients with insulin resistance (106), and in those with diabetes type I (107) or type II (108). The patient with IGF-I deficiency due to an IGF-I deletion had severe insulin resistance, which improved with rhIGF-I treatment (76). Patients with a heterozygous inactivating mutation of the IGF-I gene had higher fasting insulin levels than noncarriers (14). Two patients with a heterozygous IGF1R mutation had a moderate degree of insulin resistance (22, 109). The first described patient with ALS deficiency was insulin resistant (33). These results demonstrate a role of IGF-I in glucose homeostasis. Whether IGF-I directly affects insulin sensitivity or by regulating endogenous GH levels is a topic of intense research.

Body composition

GH is known to have a lipolytic effect, which is illustrated by the finding that GH treatment in GH deficiency reduces adiposity and improves lipid profiles (110). Patients with GH resistance have a markedly decreased ratio of lean mass to fat mass, indicating the lack of the direct antilipolytic effect of GH (50). In the patient with the IGF-I gene deletion, in whom the direct GH effects are intact, a low body fat content was found (19.9%), which is in line with a direct antilipolytic effect of GH (95). Total body fat content increased in this patient after 1 year of treatment with rhIGF-I, which can be explained by the fall in GH levels induced by rhIGF-I. IGF-I has no direct effects on lipolysis or lipogenesis.

Puberty and gonadal function

Puberty is delayed in all conditions associated with IGF-I deficiency: GH deficiency due to a GHRHR mutation (49), GH insensitivity caused by a GHR mutation (50, 111) or a STAT5b mutation (54), IGF-I gene deletion (76), and an inactivating IGF-I mutation (14). One female with a heterozygous IGF1R mutation had menarche at the age of 18 years (22), but one of the patients described by Abbuzahab et al. had a normal onset of puberty (18). The first patient with a mutation of the ALS gene had a delayed onset of puberty (112), but a later report showed a normal onset of puberty (34). These findings suggest that IGF-I plays a role in pubertal onset.

The pubertal growth spurt is decreased in patients with GH deficiency or resistance with normal testosterone levels. This was initially interpreted by speculating that testosterone needs the presence of normal GH secretion to exert its full growth-promoting effect (113). Later, evidence was provided that the growth-stimulating effect of testosterone in puberty may be primarily caused by conversion to estrogens and that estrogens are responsible for the pubertal growth spurt and epiphysial closure (114).

IGF-I−/− mice are infertile. Males have drastically reduced testosterone levels, caused by a significant developmental delay of Leydig cells. Females fail to ovulate and possess an infantile uterus with hypoplastic endometrium (115). It is difficult to hypothesize on the role of GH and IGF-I in reproductive function in the human, as most reported patients with GH–IGF-I defects are too young. Patients with GHRHR (116) and GHR mutations are reported to be fertile. Gonadal function of a 30-year-old patient with STAT5b mutation was normal (54). The 55-year-old patient with an inactivating IGF-I gene mutation had a small testicular volume, low inhibin B levels, and elevated FSH levels, indicating compromised Sertoli cell function and impaired spermatogenesis (14). The role of IGF-I deficiency in the partial gonadal failure is unclear, as this patient underwent a bilateral inguinal hernia operation, with possible damage to the testicles. Patients with a heterozygous deletion or mutation of the IGF-I (13, 14) or IGF1R gene (22) are fertile. More patients and accurate follow-up at adult age will contribute to unraveling the role of IGF-I in human reproduction.
Immune system

It has been well established that GH and IGF-I affect the development and function of the immune system (117). Most defects in the GH–IGF-I axis are not associated with immune disorders, except for the STAT5b mutation. STAT proteins are involved in the signaling pathway of cytokine receptors (118) and the STAT5b−/− mouse exhibits a severe immunologic phenotype (119). So far, five females and one male with a STAT5b mutation have been reported (52–54, 66, 77). Five patients have signs of immune deficiency. Clinically, this results in lymphoid interstitial pneumonia due to Pneumocystis carinii (52), recurrent pulmonary infections (53, 77), recurrent infections of skin and respiratory tract, severe chronic lung disease, and herpetic keratitis (66). One patient suffers from juvenile idiopathic arthritis (53). The 30-year-old male patient has no history or signs of immune deficiency (120). Thus, in the human, an intact STAT5b is not obligatory for a normal immune phenotype.

We have described a patient with partial GH insensitivity and severe immune deficiency due to a mutation of I-KBz, disturbing the NF-κB signaling pathway (121). In vitro studies have shown that GH binding to the GHR can promote the NF-κB signaling pathway (122). Another patient with severe combined immunodeficiency and GH insensitivity has been described (123). This patient has a mutation of the IL2Rγ chain gene, suggesting a common underlying pathogenic mechanism for the endocrinological and immunological problems.

More reports on patients with combined growth and immune disorders are needed to increase our knowledge on the interaction between the immune system and the GH–IGF-I axis.

Longevity

Several lines of evidence suggest an inverse relationship between body size and lifespan in mice (124). For example, Laron mice live up to 55% longer than normal mice (125). Genetic studies in various experimental models suggest that the aging process is regulated by genes that encode proteins from the GH–IGF-I axis. Exciting studies in IGFR1−/+ mice with 50% reduction in receptor level show that females live 33% longer and males 16% longer. The longer lifespan could not be attributed to other factors and the authors conclude that IGF-I may be a central regulator of mammalian lifespan (126). At the cellular level, fibroblasts with a reduced number of receptors are better able to survive oxidative stress. By causing damage to DNA, protein, lipids, and cellular components, oxidative stress is the major determinant of the aging process. At the molecular level, the intracellular signaling pathway is downregulated. Repressing intracellular signals of insulin and IGF-I is an evolutionarily conserved mechanism for extending lifespan.

Caloric restriction also has a positive effect on lifespan. Mild food restriction in normal and the Ames dwarf mice demonstrate changes in the expression of genes related to insulin and IGF-I signaling pathways (127). These changes may cause the animals to become more sensitive to insulin. Since insulin sensitive mutant animals live longer, it is suggested that these genes may play a role in aging and lifespan determination. Studies in the human are limited.

Diagnostic approach

The number of patients with defects in the GH–IGF-I axis is still small, but we believe that they represent the tip of the iceberg. Future studies aimed at detecting known or unknown molecular defects in patients with short stature will undoubtedly make the tip of the iceberg grow.

The diagnostic process to reveal an abnormality in the GH–IGF-I axis begins with an alert physician, who is not satisfied with the diagnosis of idiopathic short stature.

The medical history should include birth weight, length, and head circumference, as low values of these parameters for gestational age are features of a genetic defect in IGF-I, IGFR1, or a not yet described IGF-I signaling disorder. It cannot be stressed enough that measurement of length at birth is very important to detect underlying pathology, and the fear that stretching the legs could be harmful for the hip joint is unjustified (128). Careful evaluation of milestones in development is necessary to have an impression of the psychomotor development. Family history should include height of other family members and, if possible, birth data. The presence of hearing abnormalities in a family should alert the physician to consider an IGF-I defect.

After excluding organic and systemic disorders like Celiac disease and Turner Syndrome, the IGF-I and IGFBP-3 level will determine the follow-up. We recently presented guidelines for the diagnostic process of patients with severe short stature of unknown origin (129).

The procedure for detailed functional and genetic analysis of a patient with short stature and a possible defect in the GH–IGF-I axis depends on the local setting. In the Leiden University Medical Center, the Leiden Growth Genetics Working Group, consisting of pediatric and adult endocrinologists, clinical and molecular geneticists, molecular biologists, and interested physicians meet to discuss the locally, nationally, and internationally referred patients. The referring physician is asked to complete a form to register all the information that is necessary to make a presumptive diagnosis, including phenotypic features of the patient and his or her family and biochemical measurements (IGF-I, IGFBP-3, and GH stimulation test). One of the members of the group assesses the information and can advise on additional testing, for example an IGF-I generation test, measurement of other binding proteins,
GH-binding protein, or ALS. After presentation of the patient and discussion, the decision for the next diagnostic step is made, which can be sequencing a specific gene, multiplex ligation-dependent probe amplification analysis, single nucleotide polymorphism array, or detailed functional experiments.

**Implications for the patient**

Idiopathic short stature is an unsatisfactory diagnosis for the physician as well as for the patient. To find the cause of short stature is important for the patient for several reasons. First, with a definite diagnosis the often long-lasting diagnostic process will come to an end. Secondly, it will be possible to give information on the specific defect and accompanying problems; for example, lifestyle advice in case of higher risk of insulin resistance in patients with a heterozygous IGF1R mutation or prevention of osteoporosis in patients with ALS deficiency. Finally, therapeutic options can be discussed. It has been reported that GH therapy in patients with a heterozygous IGF1R mutation or deletion improves growth and head circumference (18, 30, 109, 130). In the late 1980s, trials with rhIGF-I started in patients with GHR defects. Approximately 60 children have been treated with rhIGF-I injections for 2 years or longer. Height SDS increases, although not as much as GH treatment in GH deficient patients (131). The explanation for the modest growth response to rhIGF-I is probably the absence of direct GH effects at the level of the growth plate, including enhancement of local IGF-I production. Recently, an rhIGF-I–rhIGFBP-3 complex, with a longer half-life, has been developed as therapeutic agent. Trials in patients with GH insensitivity are currently in progress (132).

**Future perspectives**

Future research should be focused on identifying patients with established defects in the GH–IGF-I axis and to carefully evaluate the clinical and biochemical features. Genetic defects in the GH–IGF-I axis are rare and international collaboration will increase the knowledge on the role of the GH–IGF-I axis in growth and development. Finally, it will be a challenge to find new defects in the GH–IGF-I axis in order to unravel the molecular mechanisms that are responsible for the effects of GH and IGF-I on pre- and postnatal growth and development.

**Disclosure**

This paper forms part of a European Journal of Endocrinology supplement, supported by Ipsen. The authors disclose: J.M. Wit has received a research grant from Ipsen and is member of an advisory board of Ipsen. This article was subject to rigorous peer review before acceptance and publication.

**References**


www.eje-online.org


Hwa V, Little B, Adiyaman P, Kofeed EM, Pratt KL, Ocçal G, Berberoglu M & Rosenfeld RG. Severe growth hormone


100 Riddlestrale M. Signalizing role for the insulin-like-effects of growth hormone – another example of a classical hormonal negative feedback loop. Current Drug Targets. Immune Endocrine Metabolic Disorders 2005 5 79–92.


Kamp HJ. Walenkamp MJE & Wit JM. Growth hormone treatment is efficacious in short stature due to a heterozygous missense mutation in the tyrosine kinase domain of the IGF-I receptor. *Hormone Research* 2007 68(Suppl 1) 170.


Kamp HJ. Walenkamp MJE & Wit JM. Growth hormone treatment is efficacious in short stature due to a heterozygous missense mutation in the tyrosine kinase domain of the IGF-I receptor. *Hormone Research* 2007 68(Suppl 1) 170.

